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To the Editor:
We read with interest the findings of Peters et al in patients with severe asthma who 
reported an increase in baseline circulating interleukin-6 (IL6) levels of 1 pg/ul was 
associated with a 10% increased risk of an exacerbation over 3 years and was 14% when 
excluding patients on oral corticosteroids (1). Elevated levels of IL6 in induced sputum in 
patients with asthma are related to impaired lung function (2, 3). 
IL6 is also a key component of the cytokine response in viral illness. For example in 
hospitalized patients with severe COVID-19 circulating levels of IL6 are the strongest 
predictor of the need for mechanical ventilation . In the in vitro murine model of acute lung 
injury systemic IL6 levels are suppressed by both budesonide and formoterol (4). 
Furthermore in primary airway epithelial cell cultures pre-treatment with budesonide, 
formoterol and glycopyrronium inhibited IL6 production after infection with the common cold 
coronavirus (HCoV-229E) (5). Single inhaler therapy comprising  beclomethasone , 
formoterol and glycopyrronium reduces exacerbations in patients with uncontrolled  asthma 
with persistent airflow limitation (6). Hence we would be interested to know whether such 
patients who have higher levels of circulating IL6 might benefit more from such triple therapy 
in terms of protection from viral induced exacerbations including SARS-CoV2.
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